{"id":110041,"date":"2026-04-08T12:58:58","date_gmt":"2026-04-08T10:58:58","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/"},"modified":"2026-04-08T14:46:52","modified_gmt":"2026-04-08T12:46:52","slug":"gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/","title":{"rendered":"GAT Therapeutics and the University of Barcelona outline a new therapeutic strategy for interstitial lung diseases"},"content":{"rendered":"

A team from the University of Barcelona (UB), through the TECNIO Drug Development Service (SDM) group, is participating in a public\u2013private consortium to develop a new drug with an innovative compound for the treatment of these diseases. The project is led by the biopharmaceutical company GAT Therapeutics<\/a>, located at the University of Barcelona Science Park (PCB-UB) and aims to carry out the necessary studies to advance this innovative compound to phase II clinical trials. The Vall d\u2019Hebron Research Institute and the Research Foundation of the General University Hospital of Valencia are also collaborating in the project.<\/strong><\/p>\n

Interstitial lung diseases are a diverse group of conditions characterised by inflammation and fibrosis of the lungs, leading to worsening respiratory symptoms and a decline in lung function, in some cases potentially severe.<\/p>\n

\u201cThe success of this project could open new clinical opportunities for the treatment of interstitial lung diseases and other fibrotic conditions, for which there are currently no effective treatments and whose incidence has increased,\u201d highlights Dr Pilar P\u00e9rez Lozano<\/strong>, researcher at the Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry of the Faculty of Pharmacy and Food Sciences, who leads UB\u2019s participation in the consortium.<\/p>\n

GTX-11, developed by GAT Therapeutics and protected by patent, is a small oral molecule that modulates the TGF\u03b2 signalling pathway, a key factor in fibrotic processes, characterised by the excessive accumulation of collagen fibres in tissues that alters the normal structure and function of organs.<\/p>\n

\u201cThis innovative approach has the potential to act on the three main pathological axes of the disease \u2014fibrosis, inflammation, and endothelial and cardiovascular dysfunction\u2014 with the aim of offering an alternative with a favourable safety profile compared to current treatments,\u201d explains Eug\u00e8nia Ruiz<\/strong>, CSO of GAT Therapeutics.<\/p>\n

In addition, this new therapy could be used in combination with standard treatments, increasing its potential to prevent the severe consequences of these diseases. \u201cThese combined and personalised therapies are essential to address the notable interpatient variability observed in these conditions,\u201d adds the researcher.<\/p>\n

Successful results in preclinical studies and phase I<\/strong><\/h3>\n

Preclinical studies with the new compound have shown that it reduces fibrosis and inflammation in models of pulmonary and hepatic fibrosis. In addition, it has demonstrated improved endothelial function \u2014a key factor in fibrosis progression\u2014 and a solid safety and efficacy profile.<\/p>\n

At the same time, GTX-11 has successfully completed a phase I clinical trial in healthy volunteers, confirming its good tolerability and a pharmacokinetic profile suitable for further clinical development.<\/p>\n

The current project aims to advance GTX-11 to phase II clinical trials by improving the drug formulation and further characterising its functionality in complementary preclinical models, where combinations with other drugs will also be evaluated. Combination therapies are key to addressing high interpatient variability, thus promoting more personalised treatments.<\/p>\n

Potential technological platform for other fibrotic diseases<\/strong><\/h3>\n

The technology validated in this project has potential applications in other fibrotic disorders for which there is currently no effective treatment, such as liver fibrosis or scleroderma. \u201cAchieving the expected results would represent a significant advance in this field, as it would open the door to new therapeutic approaches and the development of a platform based on this new drug,\u201d emphasises Dr P\u00e9rez<\/strong>, UB researcher.<\/p>\n

To achieve these goals, the consortium will bring together a team of researchers with proven expertise across multiple disciplines, ranging from cell biology, immunology and bioinformatics to the development of a stable pharmaceutical formulation ensuring maximum bioavailability of the active ingredient. The Drug Development Service will be responsible for this final stage: \u201cThis development represents a crucial step in consolidating GTX-11 as a robust therapeutic option, meeting the highest regulatory standards worldwide,\u201d concludes P\u00e9rez Lozano<\/strong>.<\/p>\n

The project, entitled \u201cFinal preclinical studies for the development of new molecules for the treatment of fibrotic diseases (DEFIBER IV)\u201d, will run for three years and has the reference CPP2024-011409. The University of Barcelona, through the TECNIO SDM group, has received \u20ac231,820 in funding under the 2024 call for public\u2013private collaboration projects, funded by the Spanish Ministry of Science, Innovation and Universities, the State Research Agency and FEDER funds.<\/p>\n

\u00bb Link to the news: <\/strong>Fundaci\u00f3n Bosch i Gimpera website [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

A team from the University of Barcelona (UB), through the TECNIO Drug Development Service (SDM) group, is participating in a public\u2013private consortium to develop a new drug with an innovative…<\/p>\n","protected":false},"author":14,"featured_media":110033,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[90],"tags":[389],"class_list":["post-110041","post","type-post","status-publish","format-standard","has-post-thumbnail","category-entities","tag-gat-therapeutics"],"acf":[],"yoast_head":"\nGAT Therapeutics and the University of Barcelona outline a new therapeutic strategy for interstitial lung diseases - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"The project aims to carry out the necessary studies to advance this innovative compound to phase II clinical trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GAT Therapeutics and the University of Barcelona outline a new therapeutic strategy for interstitial lung diseases - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"The project aims to carry out the necessary studies to advance this innovative compound to phase II clinical trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T10:58:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T12:46:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/04\/1775642177184-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"GAT Therapeutics and the University of Barcelona outline a new therapeutic strategy for interstitial lung diseases\",\"datePublished\":\"2026-04-08T10:58:58+00:00\",\"dateModified\":\"2026-04-08T12:46:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\\\/\"},\"wordCount\":708,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1775642177184-1.jpg\",\"keywords\":[\"GAT Therapeutics\"],\"articleSection\":[\"ENTITIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\\\/\",\"name\":\"GAT Therapeutics and the University of Barcelona outline a new therapeutic strategy for interstitial lung diseases - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1775642177184-1.jpg\",\"datePublished\":\"2026-04-08T10:58:58+00:00\",\"dateModified\":\"2026-04-08T12:46:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"description\":\"The project aims to carry out the necessary studies to advance this innovative compound to phase II clinical trials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1775642177184-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1775642177184-1.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GAT Therapeutics and the University of Barcelona outline a new therapeutic strategy for interstitial lung diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GAT Therapeutics and the University of Barcelona outline a new therapeutic strategy for interstitial lung diseases - Parc Cient\u00edfic de Barcelona","description":"The project aims to carry out the necessary studies to advance this innovative compound to phase II clinical trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/","og_locale":"en_US","og_type":"article","og_title":"GAT Therapeutics and the University of Barcelona outline a new therapeutic strategy for interstitial lung diseases - Parc Cient\u00edfic de Barcelona","og_description":"The project aims to carry out the necessary studies to advance this innovative compound to phase II clinical trials.","og_url":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2026-04-08T10:58:58+00:00","article_modified_time":"2026-04-08T12:46:52+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/04\/1775642177184-1.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"GAT Therapeutics and the University of Barcelona outline a new therapeutic strategy for interstitial lung diseases","datePublished":"2026-04-08T10:58:58+00:00","dateModified":"2026-04-08T12:46:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/"},"wordCount":708,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/04\/1775642177184-1.jpg","keywords":["GAT Therapeutics"],"articleSection":["ENTITIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/","url":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/","name":"GAT Therapeutics and the University of Barcelona outline a new therapeutic strategy for interstitial lung diseases - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/04\/1775642177184-1.jpg","datePublished":"2026-04-08T10:58:58+00:00","dateModified":"2026-04-08T12:46:52+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"description":"The project aims to carry out the necessary studies to advance this innovative compound to phase II clinical trials.","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/04\/1775642177184-1.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/04\/1775642177184-1.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/gat-therapeutics-and-the-university-of-barcelona-outline-a-new-therapeutic-strategy-for-interstitial-lung-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"GAT Therapeutics and the University of Barcelona outline a new therapeutic strategy for interstitial lung diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/110041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=110041"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/110041\/revisions"}],"predecessor-version":[{"id":110044,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/110041\/revisions\/110044"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/110033"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=110041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=110041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=110041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}